HOME ·

CSTONE PHARMA-B

CSTONE PHARMA-B (02616.HK): IND of CS5007 (EGFR/HER3 bispecific ADC) approved by NMPA, fast-tracked in 23 working days
Tags：
CSTONE PHARMA-B02616.HKClinical Trial
2026-08-21
CSTONE PHARMA-B (02616.HK): Clinical Data of CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) Selected for ESMO 2026, Two Rapid Oral Presentations Scheduled
Tags：
CSTONE PHARMA-B02616.HKESMO 2026
2026-07-20
CSTONE PHARMA-B(02616.HK): Enters Exclusive Commercialization Partnership with Arrotex for Sugemalimab in Australia and New Zealand
Tags：
CSTONE PHARMA-B02616.HKexclusive commercialization partnership
2026-06-25
CStone Pharma-B (02616.HK): CS5007 Global Phase I Trial Initiated, Approved by Australian HREC
Tags：
CSTONE PHARMA-B02616.HK
2026-06-12
CSTONE PHARMA-B(02616.HK): Proposes Open-Market Share Repurchase of Up to 136.45 Million Shares
Tags：
CSTONE PHARMA-B02616.HKShare Repurchase
2026-05-13